Eric Topol

They get people bristled that, oh, I don't want to do this.

I don't want to have my junk food tax.

I live on junk food.

Who knows what the comeback could be?

However, at the individual level,

Again, because your book gets into both levels.

And at the individual level, there's so much, if people want to know the risk and they zoom in on how they can prevent that condition,

That is something that we didn't have.

It used to be the Cassandra curse was I don't want to know ApoE4 status because I don't want to know if I'm a high risk for Alzheimer's.

Now we're at a time where we should be able to prevent Alzheimer's if we go after this.

In fact, as you know, there's a couple of trials that are going to be out soon in the weeks ahead that are testing a GLP-1 drug, Ozempic.

Two big trials, Evoke and Evoke Plus against Alzheimer's.

These are people with mild Alzheimer's.

They're not even preventing Alzheimer's in the first place.

If that hits, oh my gosh.

But I think we share the prevention excitement.

And I want to nail you down at the personal level.

And soon it'll be 10-year LPA low too.

You got a drug coming for that one, yeah.

Yeah, and they're tough to eradicate or